BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36150914)

  • 21. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
    Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
    Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HPV testing with cytology triage for cervical cancer screening in routine practice.
    Louvanto K; Chevarie-Davis M; Ramanakumar AV; Franco EL; Ferenczy A
    Am J Obstet Gynecol; 2014 May; 210(5):474.e1-7. PubMed ID: 24373948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania.
    Şuteu O; Blaga ML; Nygård M; Leinonen MK; Nicula F; Păiş R; Coza D; Cadariu PA; Melnic A; Andreassen T; Hashim D; Weiderpass E
    Eur J Cancer Prev; 2020 Mar; 29(2):141-148. PubMed ID: 31033568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
    Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
    Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?
    Saraiya M; Berkowitz Z; Yabroff KR; Wideroff L; Kobrin S; Benard V
    Arch Intern Med; 2010 Jun; 170(11):977-85. PubMed ID: 20548011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
    Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
    JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.
    Leinonen MK; Nieminen P; Lönnberg S; Malila N; Hakama M; Pokhrel A; Laurila P; Tarkkanen J; Anttila A
    BMJ; 2012 Nov; 345():e7789. PubMed ID: 23197596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of human papillomavirus DNA in routine cervical scraping samples: use for a national cervical cancer screening program in a developing nation.
    Othman N; Othman NH
    Asian Pac J Cancer Prev; 2014; 15(5):2245-9. PubMed ID: 24716964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China.
    Tao X; Griffith CC; Zhou X; Wang Z; Yan Y; Li Z; Zhao C
    Cancer Cytopathol; 2015 Jul; 123(7):421-7. PubMed ID: 25955972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening trial of human papillomavirus for early detection of cervical cancer in Santiago, Chile.
    Ferreccio C; Barriga MI; Lagos M; Ibáñez C; Poggi H; González F; Terrazas S; Katki HA; Núñez F; Cartagena J; Van De Wyngard V; Viñales D; Brañes J
    Int J Cancer; 2013 Feb; 132(4):916-23. PubMed ID: 22684726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reducing overtreatment associated with overdiagnosis in cervical cancer screening-A model-based benefit-harm analysis for Austria.
    Sroczynski G; Esteban E; Widschwendter A; Oberaigner W; Borena W; von Laer D; Hackl M; Endel G; Siebert U
    Int J Cancer; 2020 Aug; 147(4):1131-1142. PubMed ID: 31872420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
    Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
    BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cervical cancer screening in Belgium and overscreening of adolescents.
    Van Kerrebroeck H; Makar A
    Eur J Cancer Prev; 2016 Mar; 25(2):142-8. PubMed ID: 25812038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer.
    Gyllensten U; Sanner K; Gustavsson I; Lindell M; Wikström I; Wilander E
    Br J Cancer; 2011 Aug; 105(5):694-7. PubMed ID: 21811250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical follow-up practices after cervical cancer screening by co-testing: A population-based study of adherence to U.S. guideline recommendations.
    Perkins RB; Adcock R; Benard V; Cuzick J; Waxman A; Howe J; Melkonian S; Gonzales J; Wiggins C; Wheeler CM;
    Prev Med; 2021 Dec; 153():106770. PubMed ID: 34416221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cervical cancer screening and subsequent procedures in women under the age of 25 years between 2007 and 2013 in France: a nationwide French healthcare database study.
    Maura G; Chaignot C; Weill A; Alla F; Heard I
    Eur J Cancer Prev; 2018 Sep; 27(5):479-485. PubMed ID: 28368950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protecting the underscreened women in developed countries: the value of HPV test.
    Ibáñez R; Autonell J; Sardà M; Crespo N; Pique P; Pascual A; Martí C; Fibla M; Gutiérrez C; Lloveras B; Moreno-Crespi J; Torrent A; Baixeras N; Alejo M; Bosch FX; de Sanjosé S
    BMC Cancer; 2014 Aug; 14():574. PubMed ID: 25102758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human papillomavirus testing in primary cervical screening and abnormal Papanicolaou management.
    Cox JT
    Obstet Gynecol Surv; 2006 Jun; 61(6 Suppl 1):S15-25. PubMed ID: 16729900
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.